Tempus AI, Inc. (TEM)

NMS – Real vaqt narxi. Valyuta: USD

54.61

-1.08 (-1.94%)

Yopilishda: Aug 12, 2026, 3:59 PM EDT

54.52

-0.09 (-0.16%)

Bozordan keyin: Aug 12, 2026, 4:02 PM EDT

12.08.2026

Is Tempus AI Worth Buying as Growth Improves but Valuation Stays High?

TEM's faster growth, rising data demand and reimbursement potential strengthen the bull case, but high valuation and cash burn keep risks in focus.

11.08.2026

Tempus Q2 Earnings Call Highlights Data Growth and Pricing Upside

TEM raises its 2026 revenue outlook as oncology testing, data demand and FDA-linked pricing gains support growth and cash flow improvement.

06.08.2026

CellCarta Adds Tempus to CDx Commercialization Lab Network

Tempus joins as a second commercial laboratory partnership to support oncology-focused access within CellCarta's CDx Accelerator Model. MONTREAL, Aug. 6, 2026 /PRNewswire/ -- CellCarta, a global CRO laboratory supporting the biopharmaceutical industry, today announced a strategic collaboration with Tempus AI, Inc. (NASDAQ: TEM).

04.08.2026

Tempus Study Published in Nature Medicine Demonstrates Best-in-Class Performance of PRISM2 Across Diagnostic and Prognostic Applications

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced study results demonstrating that PRISM2, a multimodal slide-level pathology foundation model developed in collaboration with researchers from Microsoft, can perform clinically important diagnostic tasks using simple prompts and can be leveraged for a variety of downstream applications. The results were published in Nature Medici.

03.08.2026

PERSONALIS SHAREHOLDER ALERT: PSNL Shareholders Interested in Pursuing Potential Claims Should Contact Julie & Holleman Regarding Proposed Sale to Tempus

NEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Julie & Holleman LLP, a nationally recognized shareholder rights firm, is investigating the proposed acquisition of Personalis, Inc. (Nasdaq: PSNL) by Tempus AI, Inc. (Nasdaq: TEM), an existing Personalis shareholder and strategic partner. For a free consultation, please visit https://julieholleman.com/personalis-inc/.

Videolar

No Data

There is no data to display

Press-relizlar

06.08.2026

CellCarta Adds Tempus to CDx Commercialization Lab Network

04.08.2026

Tempus Study Published in Nature Medicine Demonstrates Best-in-Class Performance of PRISM2 Across Diagnostic and Prognostic Applications

03.08.2026

PERSONALIS SHAREHOLDER ALERT: PSNL Shareholders Interested in Pursuing Potential Claims Should Contact Julie & Holleman Regarding Proposed Sale to Tempus

Tempus AI, Inc. (TEM)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Tempus AI, Inc. (TEM)

Is Tempus AI Worth Buying as Growth Improves but Valuation Stays High?

Tempus Q2 Earnings Call Highlights Data Growth and Pricing Upside

CellCarta Adds Tempus to CDx Commercialization Lab Network

Tempus Study Published in Nature Medicine Demonstrates Best-in-Class Performance of PRISM2 Across Diagnostic and Prognostic Applications

PERSONALIS SHAREHOLDER ALERT: PSNL Shareholders Interested in Pursuing Potential Claims Should Contact Julie & Holleman Regarding Proposed Sale to Tempus

Videolar

No Data

Press-relizlar

CellCarta Adds Tempus to CDx Commercialization Lab Network

Tempus Study Published in Nature Medicine Demonstrates Best-in-Class Performance of PRISM2 Across Diagnostic and Prognostic Applications

PERSONALIS SHAREHOLDER ALERT: PSNL Shareholders Interested in Pursuing Potential Claims Should Contact Julie & Holleman Regarding Proposed Sale to Tempus

Is Tempus AI Worth Buying as Growth Improves but Valuation Stays High?

Tempus Q2 Earnings Call Highlights Data Growth and Pricing Upside

CellCarta Adds Tempus to CDx Commercialization Lab Network

Tempus Study Published in Nature Medicine Demonstrates Best-in-Class Performance of PRISM2 Across Diagnostic and Prognostic Applications

PERSONALIS SHAREHOLDER ALERT: PSNL Shareholders Interested in Pursuing Potential Claims Should Contact Julie & Holleman Regarding Proposed Sale to Tempus

Videolar

No Data

Press-relizlar

CellCarta Adds Tempus to CDx Commercialization Lab Network

Tempus Study Published in Nature Medicine Demonstrates Best-in-Class Performance of PRISM2 Across Diagnostic and Prognostic Applications

PERSONALIS SHAREHOLDER ALERT: PSNL Shareholders Interested in Pursuing Potential Claims Should Contact Julie & Holleman Regarding Proposed Sale to Tempus

Search stocks

Tempus AI, Inc. (TEM)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Tempus AI, Inc. (TEM)

Is Tempus AI Worth Buying as Growth Improves but Valuation Stays High?

Tempus Q2 Earnings Call Highlights Data Growth and Pricing Upside

CellCarta Adds Tempus to CDx Commercialization Lab Network

Tempus Study Published in Nature Medicine Demonstrates Best-in-Class Performance of PRISM2 Across Diagnostic and Prognostic Applications

PERSONALIS SHAREHOLDER ALERT: PSNL Shareholders Interested in Pursuing Potential Claims Should Contact Julie & Holleman Regarding Proposed Sale to Tempus

Videolar

No Data

Press-relizlar

CellCarta Adds Tempus to CDx Commercialization Lab Network

Tempus Study Published in Nature Medicine Demonstrates Best-in-Class Performance of PRISM2 Across Diagnostic and Prognostic Applications

PERSONALIS SHAREHOLDER ALERT: PSNL Shareholders Interested in Pursuing Potential Claims Should Contact Julie & Holleman Regarding Proposed Sale to Tempus

Is Tempus AI Worth Buying as Growth Improves but Valuation Stays High?

Tempus Q2 Earnings Call Highlights Data Growth and Pricing Upside

CellCarta Adds Tempus to CDx Commercialization Lab Network

Tempus Study Published in Nature Medicine Demonstrates Best-in-Class Performance of PRISM2 Across Diagnostic and Prognostic Applications

PERSONALIS SHAREHOLDER ALERT: PSNL Shareholders Interested in Pursuing Potential Claims Should Contact Julie & Holleman Regarding Proposed Sale to Tempus

Videolar

No Data

Press-relizlar

CellCarta Adds Tempus to CDx Commercialization Lab Network

Tempus Study Published in Nature Medicine Demonstrates Best-in-Class Performance of PRISM2 Across Diagnostic and Prognostic Applications

PERSONALIS SHAREHOLDER ALERT: PSNL Shareholders Interested in Pursuing Potential Claims Should Contact Julie & Holleman Regarding Proposed Sale to Tempus